"name","description","rationale","label","uuid:ID","instanceType","id"
"Study Design 1","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","cd49efd4-29d9-4d46-87b4-6d33d8d9d872","StudyDesign","StudyDesign_1"
